

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

TRANSCENTA ANNOUNCES STRATEGIC COLLABORATION AND NON-EXCLUSIVE LICENSING AGREEMENT TO ADVANCE INTEGRATED CONTINUOUS BIOMANUFACTURING AND EXPAND GLOBAL ACCESS TO AFFORDABLE BIOLOGICS

This announcement is made by Transcenta Holding Limited (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but not otherwise defined shall have the same meanings ascribed thereto in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“**EirGenix**”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.

Under the agreement, the Company will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages. The Company will be eligible to receive a substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies, reflecting the long-term value both companies expect to create through this collaboration.

The HiCB platform is designed to deliver greater process efficiency, improve process control and product consistency, and significantly reduce cost of goods compared to conventional fed-batch manufacturing process, ultimately contributing to expanded global patient access to high-quality, affordable biologics.

Under this collaboration, EirGenix will adopt the Company’s HiCB platform to support its biologics development programs and manufacturing operations. EirGenix plans to apply the HiCB platform to serve CDMO clients pursuing intensified and continuous manufacturing solutions.

“We are pleased to share our HiCB platform, a result of the Company’s leadership in highly intensified continuous bioprocessing, with EirGenix who share our vision of transforming biologics manufacturing,” said Dr. Xueming Qian, Chairman and CEO of the Company. “By enabling others to implement HiCB, we can collectively advance affordability of and global access to innovative biologics. The proceeds from this and future collaborations will be reinvested to further strengthen our technology platform and advance our R&D pipeline to deliver next-generation, best in class therapeutics.”

By Order of the Board
Transcenta Holding Limited
Xueming Qian
*Executive Director, Chairman and
Chief Executive Officer*

Hong Kong, December 29, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.